The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kelsian Group Ltd
F:CY4
|
AU |
|
E
|
Effecten-Spiegel AG
XMUN:EFS
|
DE |
|
C
|
Concreat Holdings Philippines Inc
XPHS:CHP
|
PH |
|
S
|
Suntrust Resort Holdings Inc
XPHS:SUN
|
PH |
|
Manganese X Energy Corp
F:9SC
|
CA |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
US |
|
P
|
Pakgen Power Ltd
KAR:PKGP
|
PK |
|
D
|
Dewan Cement Ltd
KAR:DCL
|
PK |
|
Verbio SE
OTC:VBVBF
|
DE |
|
S
|
Sevenet SA
WSE:SEV
|
PL |
|
B
|
Belle Corp
XPHS:BEL
|
PH |
|
E
|
Euronext Athens Holding SA
XMUN:HEE
|
GR |
|
Unilever Indonesia Tbk PT
F:UTG
|
ID |
|
Verastem Inc
F:2VSA
|
US |
|
D
|
Domino's Pizza Group PLC
F:DKOB
|
UK |
|
K
|
Kohinoor Energy Ltd
KAR:KOHE
|
PK |
|
D
|
Deutsche Grundstuecksauktionen vormals Berliner Grundstuecksauktionen AG
DUS:DGR
|
DE |
|
C
|
Chibougamau Independent Mines Inc
F:CLL1
|
CA |
|
Firstcash Holdings Inc
F:FF60
|
US |
|
A
|
Amgen Inc
F:AMG
|
US |
|
PHX Energy Services Corp
TSX:PHX
|
CA |
|
H
|
Heungkuk Metaltech Co Ltd
KOSDAQ:010240
|
KR |
|
S
|
Shurgard Self Storage Ltd
F:S8V
|
GG |
|
Eterna Therapeutics Inc
NASDAQ:ERNA
|
US |
Kelsian Group Ltd (CY4)’s 12-month stock price forecast through October 2027 has a consensus target of €3.57, implying 50% upside. The forecast is based on price targets from 10 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
CY4 is 3.57 EUR with a low forecast of 2.86 EUR and a high forecast of 4.17 EUR.
Over the last 9 years, the compound annual growth rate for Revenue has been 32%. The projected CAGR for the next 4 years is 3%.
Over the last 9 years, the compound annual growth rate for Gross Profit has been 25%. The projected CAGR for the next 4 years is 5%.
Over the last 9 years, the compound annual growth rate for Operating Income has been 17%. The projected CAGR for the next 4 years is 5%.
Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 21%.
Over the last 9 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 4 years is 15%.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more